X

Drug Profile

SPD 756

Alternative Names: BCH 13520

Latest Information Update: 16 Jan 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shire Pharmaceuticals Group
Developer Shire
Class Antivirals; Purines; Small molecules
Mechanism of Action Nucleoside reverse transcriptase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued HIV infections

Most Recent Events

08 Jan 2019 Shire has been acquired and merged into Takeda
22 Mar 2004 SPD 756 is available for partnering (http://www.shire.com)
15 Nov 2002 A preclinical study has been added to the Viral Infections pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com